Coeur Mining Free cash flow decreased by 14.8% to $266.76M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1412.8%, from $17.63M to $266.76M. Over 3 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 49.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$20.16M | -$49.42M | -$65.93M | -$75.93M | -$50.51M | -$115.72M | -$84.58M | -$109.05M | -$46.18M | -$114.66M | -$27.44M | -$57.95M | -$36.16M | $69.08M | $17.63M | $146.14M | $188.67M | $313.27M | $266.76M |
| QoQ Change | — | -145.1% | -33.4% | -15.2% | +33.5% | -129.1% | +26.9% | -28.9% | +57.6% | -148.3% | +76.1% | -111.2% | +37.6% | +291.1% | -74.5% | +728.8% | +29.1% | +66.0% | -14.8% |
| YoY Change | — | — | — | — | -150.5% | -134.2% | -28.3% | -43.6% | +8.6% | +0.9% | +67.6% | +46.9% | +21.7% | +160.3% | +130.4% | +504.2% | +173.1% | — | >999% |